RJA
FHTX icon

Raymond James & Associates’s Foghorn Therapeutics FHTX Stock Holding History

Raymond James & Associates’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$21.4M Sell
2,297,319
-41,104
-2% -$298K 0.01% 784
2024
Q2 		$13.4M Buy
2,338,423
+107,967
+5% +$643K 0.01% 992
2024
Q1 		$15M Buy
2,230,456
+162,069
+8% +$900K 0.01% 927
2023
Q4 		$13.3M Buy
2,068,387
+642,161
+45% +$2.77M 0.01% 939
2023
Q3 		$7.13M Buy
1,426,226
+235,237
+20% +$1.81M 0.01% 1247
2023
Q2 		$8.38M Buy
1,190,989
+112,933
+10% +$790K 0.01% 1162
2023
Q1 		$6.68M Buy
1,078,056
+533,123
+98% +$3.49M 0.01% 1272
2022
Q4 		$3.48M Buy
544,933
+515,796
+1,770% +$3.89M ﹤0.01% 1665
2022
Q3 		$250K Buy
29,137
+1,000
+4% +$12.9K ﹤0.01% 3297
2022
Q2 		$383K Buy
28,137
+2,000
+8% +$25.8K ﹤0.01% 3069
2022
Q1 		$398K Buy
26,137
+13,200
+102% +$181K ﹤0.01% 3213
2021
Q4 		$296K Buy
+12,937
New +$186K ﹤0.01% 3449

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's FHTX Position: Q3 2024 in Review

Raymond James & Associates reduced its Foghorn Therapeutics (FHTX) stake by 1.8% in Q3 2024, selling an estimated $298K and leaving 2,297,319 shares worth $21.4M. The position accounts for 0.01% of the portfolio, ranked #784.

Raymond James & Associates first reported a position in FHTX in Q4 2021 and has held it in 12 quarters since. 79 funds tracked by Wall St. Rank hold FHTX as of Q3 2024.

  • Raymond James & Associates held 2,297,319 shares of Foghorn Therapeutics worth $21.4M as of Q3 2024.
  • Raymond James & Associates sold 41,104 Foghorn Therapeutics shares in Q3 2024, an estimated $298K.
  • Foghorn Therapeutics made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #784 holding.
  • Raymond James & Associates first reported a position in Foghorn Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • 79 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.